Hormone Therapy for Menopause and Premature Ovarian Insufficiency

2021 ◽  
pp. 101597
Author(s):  
Irene Lambrinoudaki ◽  
Stavroula A. Paschou
Keyword(s):  
Hormone Therapy ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency

Bone mass in women with premature ovarian insufficiency: a comparative study between hormone therapy and combined oral contraceptives

Menopause ◽  
2020 ◽  
Vol 27 (10) ◽  
pp. 1110-1116 ◽  
Author(s):  
Lívia B. Carvalho Gazarra ◽  
Camila L. Bonacordi ◽  
Daniela A. Yela ◽  
Cristina Laguna Benetti-Pinto
Keyword(s):  
Bone Mass ◽  
Comparative Study ◽  
Hormone Therapy ◽  
Oral Contraceptives ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency ◽  
Combined Oral Contraceptives

Standard hormone therapy is inadequate for bone density in premature ovarian insufficiency

2016 ◽  
Vol 33 (4) ◽  
pp. 283-286 ◽  
Author(s):  
Helena Giraldo ◽  
Cristina Benetti-Pinto ◽  
Valeska Ferreira ◽  
Heraldo Garmes ◽  
Daniela Yela ◽  
...  
Keyword(s):  
Bone Density ◽  
Hormone Therapy ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency

Sleep quality and fatigue in women with premature ovarian insufficiency receiving hormone therapy

Menopause ◽  
2019 ◽  
Vol 26 (10) ◽  
pp. 1141-1145 ◽  
Author(s):  
Cristina Laguna Benetti-Pinto ◽  
Camila Menezes ◽  
Daniela Angerame Yela ◽  
Tania Moc Cardoso
Keyword(s):  
Sleep Quality ◽  
Hormone Therapy ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency

Body composition in women with premature ovarian insufficiency using hormone therapy and the relation to cardiovascular risk markers: A case‐control study

2020 ◽  
Vol 94 (1) ◽  
pp. 111-118
Author(s):  
Alberto T. A. Freitas ◽  
Andrea E. Donovan Giraldo ◽  
Gabriela Pravatta Rezende ◽  
Daniela A. Yela ◽  
Rodrigo M. Jales ◽  
...  
Keyword(s):  
Body Composition ◽  
Cardiovascular Risk ◽  
Hormone Therapy ◽  
Case Control Study ◽  
Case Control ◽  
Premature Ovarian Insufficiency ◽  
Risk Markers ◽  
Ovarian Insufficiency ◽  
Control Study

Can hormone therapy modify pelvic floor muscle assessment and symptoms within women with premature ovarian insufficiency?

2020 ◽  
Vol 252 ◽  
pp. 624-625
Author(s):  
Julia Ferreira Fante ◽  
Luiz Gustavo Oliveira Brito ◽  
Cassia Raquel Teatin-Juliato ◽  
Cristina Laguna Benetti-Pinto
Keyword(s):  
Pelvic Floor ◽  
Hormone Therapy ◽  
Pelvic Floor Muscle ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency

scholarly journals Poor Compliance to Hormone Therapy and Decreased Bone Mineral Density in Women with Premature Ovarian Insufficiency

PLoS ONE ◽  
2016 ◽  
Vol 11 (12) ◽  
pp. e0164638 ◽  
Author(s):  
Anne Bachelot ◽  
Carole Nicolas ◽  
Solenne Gricourt ◽  
Jérôme Dulon ◽  
Monique Leban ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Hormone Therapy ◽  
Bone Mineral ◽  
Poor Compliance ◽  
Premature Ovarian Insufficiency ◽  
Mineral Density ◽  
Ovarian Insufficiency

Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases

Climacteric ◽  
2017 ◽  
Vol 20 (3) ◽  
pp. 268-273 ◽  
Author(s):  
X. Yang ◽  
C. Wang ◽  
X. He ◽  
J. Wei ◽  
Y. Wang ◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Premature Ovarian Insufficiency ◽  
Ovarian Insufficiency ◽  
Hematologic Diseases

Use of Hormone Therapy in Women with Early Menopause and Premature Ovarian Insufficiency

2021 ◽  
Author(s):  
Ivy Lersten ◽  
Elizabeth Clain ◽  
Nanette Santoro
Keyword(s):  
Hormone Therapy ◽  
Health Risks ◽  
Treatment Options ◽  
Risk Profile ◽  
Primary Ovarian Insufficiency ◽  
Premature Ovarian Insufficiency ◽  
Early Menopause ◽  
Ovarian Insufficiency ◽  
Risks And Benefits ◽  
Menopausal State

AbstractWomen with early menopause or primary ovarian insufficiency (POI) experience a menopausal state a decade or more earlier than their peers. The health consequences for POI are vast and varied with detrimental effects seen on neurological, psychological, bone, and cardiovascular systems. The risk profile of POI patients requires special attention, as they differ from a typical menopausal population. This review will explore the health risks associated with POI and examine the various treatment options and also the risks associated with hormone therapy. Given the risks and benefits, POI patients should be strongly encouraged to start hormone therapy until the median age of menopause.

Sign in / Sign up

Export Citation Format

Share Document